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a  b  s  t  r  a  c  t
Results of Chagas’ disease diagnosis show disagreement. The aim of this study was to
compare  commercial tests for Chagas’ disease serodiagnosis in southern Brazil. A total of
161 samples were evaluated. Three enzyme-linked immunosorbent assays, one indirect
hemagglutination  and one indirect immunoﬂuorescence were assessed. Trypomastigote
excreted-secreted antigen-blot was a conﬁrmatory method. From 161 samples, 65.84%
were  positive in all tests, while 34.16% presents mismatch result in at least one of the
tests.  All techniques tested presented false-positive and/or false-negative results as follows:
Enzyme-linked  immunosorbent assay 1 had more false-positive results (lower speciﬁcity),
indirect  immunoﬂuorescence had the highest rate of false-negative results (lower sen-
sitivity),  enzyme-linked immunosorbent assays had fewer false-negative results (higher
sensitivity),  while indirect hemagglutination showed no false-positive result (higher speci-ﬁcity).  Knowing the characteristics of techniques make it possible to combine them and
obtain  more reliable diagnosis. Therefore, it seems useful to combine techniques for diag-
nosing  this infection.
immunosorbent assay (ELISA), indirect hemagglutination
(IHA) and indirect immunoﬂuorescense (IIF)), there is not a
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Chagas’ disease, caused by the protozoan Trypanosoma cruzi,
constitutes  a serious public health problem in Latin Amer-
ica.  Once controlling measures against the triatomine insects
are  implemented, secondary mechanisms of transmission
become relevant, such as blood transfusion, organ transplan-
tation,  ingestion of contaminated food and transplacental
route, especially in countries where vectorial transmission
does not occur.1 In many  countries outside Latin America,
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Este é um artigo Open Access sob a licençaChagas’ disease diagnosed among immigrants from endemic
areas  is a cause for concern.2–5
The diagnosis of Chagas’ disease is difﬁcult, both in
routine laboratories dealing with suspected infections and
in  screening laboratories (blood banks, umbilical cord blood
banks,  organs donors, etc.). Although there are several tests
available  to indirect diagnosis (especially enzyme-linkedmiro Barcelos, 2350, Porto Alegre, RS 90035-903, Brazil.
gold-standard  technique, and the results obtained by differ-
ent  techniques show disagreement, with varying levels of
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ensitivity and speciﬁcity.6–8 These results may  be related
o  the parasitic form used to obtain the antigens; there are
ntigenic  differences between epimastigote and amastigote
orms,  accepting that their immunodominant fractions are
ot  the same.9 Trypomastigotes-based ELISA showed higher
peciﬁcity10,11 and, in some cases, higher sensitivity too.9 The
ource  of the strain used to obtain the antigen can produce
ifferences in technique performance, with better results
ith  antigens from local strains of T. cruzi.12–14
Nonspeciﬁc reactions, causing inconclusive or false posi-
ives  (FPs) can occur in the diagnosis of Chagas’ disease,
ost frequently by antibodies produced by patients with
eishmaniasis.9,12,15–18 Some conﬁrmatory tests have been
escribed for conventional serology in doubtful situa-
ions,  such as trypomastigote excreted-secreted antigen-blot
TESA-blot),19 INNO-LIA Chagas (line immunoassay),20 RIPA
radioimmune precipitation assay)21 and Abott Chagas
mmunoassay.22 TESA-blot shows high sensitivity and speci-
city  in different groups of patients compared to those of
onventional serological methods.23,24 It has been used as
he  gold-standard in the serology of Chagas’ disease.25 TESA-
lot  is considered positive when sera react with antigens of
30–200  kDa and/or antigens of 150–160 kDa, and some sera
lso  react with bands of 80–120 kDa (SAPA – shed acute-phase
ntigen). Several chronic patients also react with SAPA bands
lus  a band of approximately 95 kDa.19
This study was  conducted to compare different tests uti-
ized  for serodiagnosis of Chagas’ disease in patients of Rio
rande  do Sul State, Southern Brazil. In order to obtain reli-
ble  results for Chagas’ disease it is imperative to understand
he  performance of the available techniques.
aterials  and  methods
ample  collection
he tests were  evaluated in 161 serum samples from Labo-
atory  of Serology of Blood Center of Pelotas City, Brazil, that
ere  positive in at least one of the techniques utilized in this
tudy.  The Blood Center of Pelotas receives blood donors liv-
ng  in both urban and rural areas of south of Rio Grande do Sul
tate,  Southern Brazil. The samples from adults (18–65 years
ld)  were  collected and serum samples were  frozen at −20 ◦C
ntil  the end of analysis.
thics  statement
t blood collection, all subjects gave written consent to par-
icipate  in this study. Privacy and anonymity of patients were
trictly  ensured. The study was  approved by the Research
ommittee of Postgraduate Program of Universidade Federal
e  Pelotas, Brazil, and by the Blood Center of Pelotas City,
razil.
erological  methodsLISA 1 – Chagatest® (Wiener Lab, Argentina). ELISA 2 –
HAGATEK® (Biolab-Mérieux, Rio de Janeiro, Brazil). ELISA
 – EIAgen T. cruzi IgG + IgM (Adaltis, Bologna, Italy). Indirect3;1  7(2):174–178  175
hemagglutination (IHA) – Chagatest IHA® – Screening AV
(Wiener  Lab, Argentina). In case of reactive samples, quan-
titative  tests were  carried out using the same methodology,
performing serial dilutions of serum. Indirect immunoﬂuo-
rescence (IIF) – IMUNOCRUZI® (Biolab-Mérieux, Rio de Janeiro,
Brazil)  and conjugated sheep anti-IgG human marked by
ﬂuorescein  isothiocyanate, FLUOLINE® (Biolab-Mérieux, Rio
de  Janeiro, Brazil).
The  tests were evaluated as described in the speciﬁc
methodology. Positive and negative controls were always
included to validate the results.
Conﬁrmatory  test  – TESA-blot
Immunoblotting with antigen TESA (excretory–secretory anti-
gen  of T. cruzi) was used as a conﬁrmatory method19,23,24 in
samples with discordant results between the techniques and
also  in reactive samples in all tests, to assess the pattern of
bands  recognized by sera positive for T. cruzi in patients of
southern  of Brazil.
Statistical  analysis
The Cohen’s Kappa index was used to measure the magnitude
of  agreement beyond chance between serological tests and the
conﬁrmatory  method TESA-blot. Kappa values >0.81 represent
‘excellent’  agreement; those between 0.61 and 0.8 show ‘good’
agreement;  those between 0.41 and 0.6 show ‘moderate’ agree-
ment;  those between 0.21 and 0.4 show ‘weak’ agreement and
values  <0.21 represent ‘negligible’ agreement.
Results
Table 1 presents the results of 161 serum samples showing
reactivity to anti-T. cruzi by the tested techniques. The samples
were  divided into 12 groups, according to its reactivity in the
techniques  panel and were compared with TESA-blot results.
Considering  the results of conﬁrmatory testing, 122/161
(75.78%) samples were positive while 39/161 (24.12%) were
negative  for anti-T. cruzi. The 150–160 and 95 kDa bands were
showed,  in higher or lower intensity, in positive samples by
TESA-blot.  In some samples, the range of 120–210 kDa bands
related  to SAPA was evident. According to Table 1, from 161
sera  analyzed, 106 (65.84%) were positive in all commercial
tests (Table 1, group 1). When a sample was positive in all com-
mercial  tests, TESA-blot conﬁrmed the result. In the remaining
55  samples (43.16%) mismatch result was  observed with at
least  one of the tests.
All  samples showed reactivity to at least one of three types
of  ELISA tested. ELISAs 1, 2 and 3 had an index of reactivity
(OD/cut off) ranging from 0.90 to 8.30, 0.96 to 16.28 and 1.02
to  13.35, respectively. A comparison among the three ELISA
tests  showed a concordance in 123 samples (76.4%), or even,
considering the same methodology, a variation was observed
between  different types of kits. Reactivity only with one ELISA
occurred  in 21 samples, which was more  common with ELISA
1  (Table 1, groups 9, 10 and 12). Of these, only one sample
developed bands with TESA-blot. Positive samples in only
two  ELISA tests (Table 1, groups 6, 7 and 8) were  negative with
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Table 1 – Reactivity of 161 samples for Trypanosoma cruzi tested by three ELISAs, an IHA and an IIF compared with
TESA-blot result, composing 12 groups, according samples comportment in techniques panel.
Group Conventional tests results Samples frequency number (%) Positive TESA-blot
A B  C D E
1 P P P P  P 106 (65.84) 106
2 P P P P N 10 (6.21) 10
3 P P P N N 6 (3.73) 3
4 P N P N P 2 (1.24) 1
5 P P P N P 1 (0.62) 0
6 P N P N N 9 (5.59) 0
7 P P N N N 1 (0.62) 0
8 N P P N N 4 (2.48) 0
9 N N P N N 1 (0.62) 0
10 P N N N N 19 (11.8) 1
11 N P P P P 1 (0.62) 1
12 N P N N N 1 (0.62) 0
Total 161 (100) 122
– IHA
occur  with serum from patients with leishmaniasis,9,18 which
was  not a problem in this study, since this disease has not
been  reported in the region of origin of the samples. The
Table 2 – Positive and negative cases for each technique
compared with TESA-blot (conﬁrmatory method) results
and  Kappa index.
Conventional tests TESA-blot Kappa index
Positives Negatives
ELISA 1
Positives 121 33 0.21
Negatives 1 6
ELISA  2
Positives 120 10 0.77
Negatives 2 29
ELISA  3
Positives 121 19 0.61
Negatives 1 20
IHA
Positives 117 0 0.92
Negatives 5 39
IIFOrder of conventional tests: A – ELISA  1, B – ELISA  2, C – ELISA  3, D 
results.
TESA-blot. Reagent samples with ELISAs and negative with
IHA  and IIF (6/161) were 50% negative and 50% weakly positive
with  TESA-blot (Table 1, group 3). Non-reagent sample only
with  ELISA 1 (Table 1, group 11) was  positive with TESA-blot,
thus  false-negative (FN) results.
With IHA, 117 samples (72.67%) were reactive and 44
(27.33%) were  negative. This technique disagreed in isolation
with  other techniques (Table 1, group 5) in only one sample
(0.62%),  whose TESA-blot result conﬁrmed IHA result.
In  the case of IIF, 110 (68.32%) samples were positive and
51  (31.68%) were negative. The IIF disagreed with other tech-
niques  (Table 1, group 2) in 10 samples (6.21%), where IIF
showed  negative results, whereas the other four techniques
and  the TESA-blot showed positive results.
Results with ELISA, IHA and IIF were  compared with TESA-
blot,  highlighting FP and FN results of each technique (Table 2).
ELISA 1 had more  FP results (33 samples); IIF presented had
the  highest number of FN results (14 samples); the ELISAs, in
general,  showed fewer FN results (1 sample with ELISA 1 and
ELISA  3, and 2 samples with ELISA 2), whereas there was  no
FP  result with IHA.
According  to Kappa index, the agreement with the con-
ﬁrmatory method was  excellent for IHA technique, good for
ELISA  2, ELISA 3 and IIF, and weak for ELISA 1.
Discussion
As observed in this study, the discrepancy between results
of  serological tests is frequent.7,12,21,24,26–30 A comparison
of only ELISA tests in this study showed higher agreement
than in other comparative studies.7,8 The variety of T. cruzi
antigens used in the preparation of the extract utilized in
different  serological tests may  result in discrepancies in the
results  when analyzing only one sample. The heterogeneity
and  genetic variability among strains of T. cruzi are well
known,  with a predominance of one lineage or population in
a location, identiﬁed as regional strains, which modiﬁes the
biological  conditions, virulence, clinical proﬁles of the host and E – IIF. N represents negative results and P represents positive
and,  consequently, antibodies with variable performance in
diagnostic methods.31–36 The use of regional strains provides
the  best performance compared to the use of strains of vari-
ous  origins.12 Likewise, the parasitic form may  interfere with
the  proven results of serological tests, so that antigens of try-
pomastigotes, an exclusive form of Trypanosoma, have a better
speciﬁcity  and, in some cases, sensitivity.9,11 In addition to
issues  related to the kits, other interferences can be responsi-
ble  for unspeciﬁc reactions, such as inadequate samples and
biological  issues, as cross reactions or individuals on treat-
ment.  The most common cross-reactions with Chagas’ diseasePositives  108 2 0.76
Negatives 14 37
122  39



















































1b r a z j i n f e c t d i s .
ubjectivity of the reading techniques of IIF and IHA may  also
ause  variation in samples with weakly reactive results.
All  serological techniques tested presented failures for sen-
itivity  and/or speciﬁcity, considering the occurrence of FP
nd/or  FN results in all of them (Table 1). The IIF, with high-
st  number of FN, showed more  isolated non-reagent results
10/161  samples). In contrast, other studies showed 100% sen-
itivity  with IIF.7 On the other hand, the ELISA techniques in
eneral  proved to be more  sensitive. The IHA was  the tech-
ique  with the greatest speciﬁcity and was  the only one with
o  FP, while the ELISA 1 presented the lowest speciﬁcity. Also
here  was  greater speciﬁcity with IHA compared to ELISA and,
n  the other hand, greater sensitivity with ELISA.6
Considering the results of the conﬁrmatory test, when the
ample  was  positive in only one or two techniques, the trend
as  for a FP result, and the ELISA’s reactivity index was low.
he  same was  observed in the conﬁrmatory test INNO-LIA,
here the majority of negative results were detected in sera
hat  had reacted in only one of the screening techniques.20
In an attempt to improve the quality of serodiagnosis of
hagas’  disease, it seems useful to combine more  than one
echnique  for the diagnosis of this infection. The commercially
vailable diagnostic kits are produced from certain strains of T.
ruzi and marketed to different regions. Therefore, it would be
orthwhile that at least the antigenic extract used was com-
osed  of strains from different regions, with more  sensitive
nd  speciﬁc parasitic form.9,11 Additionally, a conﬁrmatory
est of a higher sensitivity and speciﬁcity should be added.23,24
onclusion
he techniques tested show disagreement in results for anti-
.  cruzi detection, conﬁrming the knowledge existing in the
iterature.  All of them presented FP and/or FN results. It is
mportant  to know the characteristics of different techniques
n  order to associate them and obtain a more  reliable and
ppropriate diagnosis to the stage of disease and patient situ-
tion.
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